Interestingly, almost all studies addressing EGFR-inhibitor-induced skin rash done in patients with metastatic colorectal cancer suggest that its severity is a suitable surrogate marker for efficacy of anti-EGFR therapy [44-47]. This evidence concerns the gene EGFR and exanthem.